GPP
TVTX icon

Great Point Partners’s Travere Therapeutics TVTX Stock Holding History

Great Point Partners’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-60,000
Closed -$922K – 52
2023
Q2 		$922K Sell
60,000
-943,000
-94% -$17.2M 0.18% 38
2023
Q1 		$22.6M Buy
1,003,000
+528,000
+111% +$11.2M 4.43% 9
2022
Q4 		$9.99M Sell
475,000
-491,108
-51% -$10.4M 1.96% 21
2022
Q3 		$23.8M Sell
966,108
-5,125
-0.5% -$132K 5.73% 5
2022
Q2 		$23.5M Sell
971,233
-38,767
-4% -$975K 5.64% 4
2022
Q1 		$26M Buy
1,010,000
+210,000
+26% +$5.58M 6.29% 3
2021
Q4 		$24.8M Buy
800,000
+175,000
+28% +$4.93M 5.52% 4
2021
Q3 		$15.2M Sell
625,000
-459,300
-42% -$8.44M 3.53% 10
2021
Q2 		$15.8M Buy
1,084,300
+490,588
+83% +$9.68M 3.32% 11
2021
Q1 		$14.8M Buy
+593,712
New +$16.4M 3.06% 16
2019
Q4 		– Sell
-1,740,000
Closed -$20.2M – 47
2019
Q3 		$20.2M Buy
1,740,000
+736,400
+73% +$12.2M 1.85% 18
2019
Q2 		$20.2M Buy
+1,003,600
New +$19.8M 2.24% 13

Other funds holding TVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Great Point Partners's TVTX Position: Q3 2023 in Review

Great Point Partners sold out of Travere Therapeutics (TVTX) in Q3 2023, closing a stake of 60,000 shares — an estimated $922K sold.

Great Point Partners first reported a position in TVTX in Q2 2019 and held it in 12 quarters. The position peaked at $26M in Q1 2022. 169 funds tracked by Wall St. Rank hold TVTX as of Q3 2023.

  • Great Point Partners reported no remaining Travere Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Great Point Partners sold 60,000 Travere Therapeutics shares in Q3 2023, an estimated $922K.
  • Great Point Partners first reported a position in Travere Therapeutics in Q2 2019 and held it in 12 quarters.
  • Great Point Partners's Travere Therapeutics position peaked at $26M in Q1 2022.
  • 169 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2023.

Based on Great Point Partners's 13F filing for Q3 2023, filed 14 Nov 2023.